Skip to Content

Takeda's New Structure for Pharmaceutical Marketing Division in Japan

OSAKA, Japan, March 20, 2007 --- Takeda Pharmaceutical Company Limited ("Takeda") announced today a reorganization of its Pharmaceutical Marketing Division responsible for domestic ethical drug business effective April 1, 2007, that is a shift from current 156 representative offices under 13 branches to 19 regional groups and 74 representative offices under 12 branches.

In Japan, a group of medical reform bills were introduced in June 2006, and accordingly, the review of provision of healthcare services in each prefecture unit, and reorganization of local healthcare provision system are currently on-going. Such movement is expected to clarify the expertise and function of every medical institution including primary care physicians, and also to promote the cooperative scheme among medical institutions specifically designed by each diseases area.

In order to fully respond to this market environmental change, this reorganization will be enable the company to conduct the promotional activities, efficiently satisfying the needs of large-scaled hospitals including those of universities with high level of expertise and the impact to each local region. Accordingly, it is expected to make it possible to conduct the activities for provision of the scientific information to healthcare providers in further carefully crafted manner.

OVERVIEW of the new structure

  1. 13 branches will be reorganized to 12 branches by combining Osaka Branch and Kobe Branch. 
  2. Establishment of 19 regional groups, responsible for university hospitals and large-scaled hospitals. 
  3. Current 156 representative offices will be reorganized to 74 offices, and the 255 area teams, reporting to sales representative office managers, are established. 4.Managers of 19 regional groups and Leaders of 255 area teams are leading the group/team, through in-depth education and guidance of each medical representative.

Posted: March 2007